New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 2, 2013
16:15 EDTIDRAIdera announces presentation of data supporting results from IMO-3100 trial
Idera Pharmaceuticals announced the presentation of new data showing that its selective Toll-like receptor antagonists, IMO-3100 and IMO-8400, normalized the gene expression of important cytokines in a preclinical study of skin inflammation that is commonly used as a model of psoriasis. The data presented by Dr. Krueger provide scientific support for the top-line results from the proof of concept Phase 2 trial of IMO-3100 in patients with psoriasis that Idera announced late last year. We look forward to presenting detailed results from the clinical trial at the International Investigative Dermatology Annual Meeting in May 2013,” commented Robert Arbeit, M.D., VP of Clinical Development at Idera. “In addition, during the first quarter, we completed the single dose portion of a Phase 1 clinical trial of IMO-8400 in healthy subjects. IMO-8400 was well-tolerated and demonstrated target engagement of TLRs 7, 8 and 9. The multiple-dose portion of the IMO-8400 Phase 1 trial is ongoing, and we anticipate data during the second quarter of 2013.”
News For IDRA From The Last 14 Days
Check below for free stories on IDRA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 7, 2014
16:13 EDTIDRAIdera says preclinical data shows inhibition of lymphoma cells
Idera Pharmaceuticals presented new preclinical data demonstrating the ability of its Toll-like receptor antagonist, IMO-8400, to inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L265P genetic mutation. These data add to the research which supports the company’s efforts to develop IMO-8400 for the treatment of genetically defined forms of B-cell lymphoma. The data build upon reports from independent investigators and provide additional evidence that the MYD88 L265P mutation, which is present in certain B-cell lymphomas, results in over-activation of TLR7 and TLR9 mediated signaling. Idera has opened enrollment in a Phase 1/2 trial of IMO-8400 designed to evaluate IMO-8400’s safety, tolerability and potential clinical activity in patients with Waldenstrom’s macroglobulinemia who are refractory to prior therapies. The company anticipates that patient treatment in this trial will begin in Q2. Idera has also submitted a separate protocol to the U.S. FDA to conduct a Phase 1/2 trial in patients with DLBCL who harbor the MYD88 L265P mutation.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use